Hangzhou-headquartered Santo Therapeutics, which has a base at Stevenage Bioscience Catalyst, says its lead program, ST002, ...

The biotechnology company disclosed interim human trial data for its RV-001 optogenetic treatment aiming to restore sight in ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial ...

This important cross-species study tests whether the corpus callosum contains parallel, segregated pathways for ipsilateral and contralateral visual-field information, rather than mixed inputs from ...

Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, ...

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

As AI billionaires cash in, they’re already gearing up to sell the public on a feel-good story no one asked for and even ...

Sparse computing enables leaner, faster AI ...

"We're off to a strong start in 2026, fueled by a strong demand and cold winter, giving us confidence in our full-year plan," said (CEO & Executive Chairman David Slater), adding, "We continue to ...

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional ...

Good morning, everyone, and thank you for joining Naturgy's First Quarter 2026 Results Presentation. This is Abel Arbat speaking from the Capital Markets team at Naturgy. Next to me sits the Global ...